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PreviewsAlternatively, glutamine might affect
mTORC1 activity through glutamine
metabolism in the tricarboxylic acid
(TCA) cycle (Dura´n et al., 2012).
Reduced glutamine import in ASCT2-
deficient T cells would reduce intracel-
lular leucine concentrations, resulting in
reduced mTORC1 signaling and atten-
uation of proinflammatory CD4+ T cell
responses (Figure 1). Indeed, TCR-stimu-
lated leucine uptake was dramatically
reduced in Asct2/ T cells; moreover,
defects in both mTORC1 activation and
Th17 differentiation could be rescued in
ASCT2-deficient T cells by the administra-
tion of exogenous leucine. Interestingly,
Cantrell and colleagues recently reported
similar defects in T cell metabolism,
mTORC1 activation, and Th1 and Th17
cell differentiation in mice harboring a
Tcell-specific deletion ofSLC7A5 (Sinclair
et al., 2013). Together these studies
provide insight into the influence of AAs
on shaping T cell-mediated immune re-
sponses, independent of their role in pro-
tein biosynthesis. It is important to note
that glutamine is not the sole AA trans-
ported by ASCT2, and whether deficiency
in the transport of other AAs contributes tothe phenotype of Asct2/ T cells remains
to be determined.
The work of Nakaya and colleagues
raises important questions regarding the
impact of nutrient availability on T cell
function. As T cells travel from sites of
immune priming in secondary lymphoid
organs to distant sites of infection, they
are likely to experience different meta-
bolic microenvironments that might
impact their function. TCR-dependent
control of nutrient transporters such as
ASCT2 might be one way that CD4+
T cells acquire sufficient nutrient levels
to maintain mTORC1 activity and T cell
effector function. Understanding the
mechanisms that coordinate—and regu-
late—proinflammatory CD4+ Th cell re-
sponses might uncover new mechanisms
for modulating T cell responses, with
applications ranging from new treatments
for autoimmune disease to improving the
effectiveness of cancer immunotherapy.
The work by Nakaya et al. (2014) indicates
that the management of metabolic re-
sources, including the import of specific
amino acids, is a critical determinant for
the proper development and function of
proinflammatory CD4+ T cell responses.ImmunityREFERENCES
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Macrophages in the gut originate from blood precursors and have distinct functional properties. In this issue
of Immunity, Zigmond et al. (2014) and Shouval et al. (2014) report that interleukin-10 drives macrophages to
express homeostatic tolerogenic functions, preventing colitis.Constant exposure to food and environ-
mental antigens and a tremendous variety
of commensal bacteria make the intestine
a vulnerable setting. Intestinal immune
cells are engaged in a robust balanced
immune response, aimed at controlling
pathogen invasion while preventing unin-
tended harmful tissue injuries. Key
players in the maintenance of gut defense
and homeostasis are intestinal mono-nuclear phagocytes, of which monocyte-
derived macrophages constitute the
most abundant population (Zigmond and
Jung, 2013). Failure in the macrophage-
mediated shaping of gut immune re-
sponses might result in deregulated
excessive inflammatory responses, as
those observed in inflammatory bowel
disorders. The immune networks govern-
ing this balance in the steady-state intes-tinal lamina propria have recently begun
to be unraveled, with the important
clinical endpoint to identify therapeutic
targets for gut chronic inflammatory dis-
eases. However, the local molecular me-
diators driving the education of intestinal
macrophages into immunomodulating
cells have not been fully identified.
This issue of Immunity features two
original articles (Zigmond et al., 2014;40, May 15, 2014 ª2014 Elsevier Inc. 637
Figure 1. A Schematic Representation of the Origin and Regulation of Intestinal
Macrophages under Homeostatic and Inflammatory Conditions
Macrophages in the gut originate from blood CX3CR1hi monocyte precursors and exert homeostatic
tolerogenic functions, mediated by expression of the IL-10R. T regulatory cells are the main source of
IL-10 upstream of the macrophage anti-inflammatory phenotype. Failure of macrophages to respond to
IL-10 leads to a proinflammatory migratory profile (including expression of Nos2, IL-23a, Ccl5, and
Ccr7 mRNA), resulting in development of colitis.
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PreviewsShouval et al., 2014) that shed light on the
immune networks modulating macro-
phage-mediated homeostasis in the gut.
They show that interleukin-10 receptor
(IL-10R) signaling in macrophages is a
key factor driving these innate immunity
cells to express homeostatic tolerogenic
functions and confirm that CX3CR1hi
macrophages are critical players in gut
health and inflammation (Figure 1).
Macrophages are both essential for gut
defense and homeostasis. Their strong
proinflammatory potential activity is kept
under control by a natural resistance
to produce inflammatory mediators in
response to pattern-recognition mole-
cules, while they preserve a variety of
homeostatic functions, scavenging bac-
teria, maintaining regulatory T cells, and
promoting epithelial cell renewal (Zig-
mond and Jung, 2013). A key molecular
mediator of these functions is IL-10. By
an elegant genetic approach selectively
targeting IL-10 or IL-10Ra in intestinal
resident macrophages, Zigmond et al.
investigate the IL-10-based regulatory
loop whereby CX3CR1hi macrophages
are polarized to an anti-inflammatory
phenotype. Their approach allows the638 Immunity 40, May 15, 2014 ª2014 Elsevidissection of the relative contribution
of IL-10 macrophage production versus
exposure and leads to the important
conclusion that macrophage release of
IL-10 is not fundamental to maintain
gut homeostasis, whereas failure of
macrophages to respond to IL-10 leads
to a proinflammatory migratory profile
(including expression of Trem-1, Nos2,
IL-23a, Ccl5, Clec9A, CCR7, and Saa3
mRNA), which is critically involved in
development of spontaneous colitis.
Along the same line, in a model of CD4+
T cell transfer induced colitis Shouval
et al. demonstrate that IL-10 sensing by
innate immune cells is critical for regu-
lating mucosal homeostasis, independent
of its effects on T cells. Further confirma-
tion of these preclinical findings is given
by the observation that IL-10R-deficient
patients with very early-onset inflamma-
tory bowel disease display defective gen-
eration and function of anti-inflammatory
macrophages.
Because of their key role in gut deci-
sions, the origin of intestinal resident
macrophages has intrigued immunolo-
gists over the past decades (Geissmann
et al., 2010). Fate-mapping studies haveer Inc.shown that, in contrast to most tissue
macrophages, which derive from cells
generated during development, intestinal
macrophages are constantly replenished
by Ly6C+ blood monocytes (Auffray
et al., 2007). However, it is unclear
whether resident macrophages adapt
their profile during inflammation, accord-
ing to microenvironmental signals (Yona
et al., 2013; Zigmond et al., 2012) or
discrete macrophage populations exist
that carry out distinct functions (Bain
et al., 2013). The continuous derivation
frommonocytes is likely to allowapeculiar
plasticity to the macrophage population,
which is reflected in different capabilities
of antigen uptake, cytokine production,
T and B cell priming, and tissue repair,
important functions that can be modu-
lated by the local environment. Sponta-
neous production of IL-10 and induction
of T regulatory cells are key strategies
that intestinal macrophages adopt to
restrain unwarranted immune responses
to dietary antigens and commensals.
Notably, the works of Zigmond and
Shouval propose a unique vista on this
issue, by showing T regulatory cells as
the main source of IL-10 upstream of the
macrophage anti-inflammatory pheno-
type. Whether other cellular components
of the gut microenvironment, including
epithelial cells, are important IL-10 sour-
ces remains to be investigated. Another
important mechanism of control of inflam-
mation is containment of macrophages
in the intestine. Notably, CX3CR1hi mac-
rophages residing in the healthy gut lack
expression of the chemokine receptor
CCR7 that is required for migration to
the mesenteric lymph nodes. IL-10 was
shown here to control CCR7 expression
on intestinal macrophages, suggesting
that their intrinsic lack of migratory capa-
city requires continuous enforcement by
environmental cues, rather than being an
inherent feature of these phagocytes.
IL-10 plays a crucial role in gut macro-
phage immunomodulatory functions.
Genome-wide association studies have
revealed a central role of the IL-10 axis
in the pathogenesis of inflammatory
bowel disease. Patients with mutations
in the IL-10 receptors that abrogate IL-
10 signaling develop early and aggressive
disease (Glocker et al., 2009). The data
presented here are consistent with this
genetic evidence and provide mecha-
nistic insight into how IL-10 maintains
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Previewscontrol of excessive inflammation in the
gut. However, IL-10 is not simply a deac-
tivator of macrophage function. Alone
or combined with LPS, it activates tran-
scriptional programs related to the con-
trol and deactivation of immunity and
inflammation, remodeling of the extracel-
lular matrix, and B cell function (Manto-
vani et al., 2004). It will be important to
assess whether induction for instance of
increased mannose receptor expression
or selected chemokines plays a role in
the homeostatic functions of intestinal
macrophages.
Therapeutic approaches aimed at re-
storing gut homeostasis during inflam-
matory bowel disorders have been the
subject of intense experimentation. IL-10
therapy in IBD patients has not resulted
in substantial clinical improvements, sug-
gesting that more refined alternative ther-
apeutic strategies should be considered.Given the complexity of the mucosal
environment and the peculiarity of its
immune populations, better knowledge
of the networks regulating the delicate
intestinal balance is required to tailor
therapeutic strategies. The data pre-
sented here suggest that macrophages
might represent a prime target to control
inflammation in the gastrointestinal tract.REFERENCES
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Cytokines can provide survival and proliferation signals to cancer cells, thus promoting tumor progression.
In this issue of Immunity, Kryczek et al. (2014) reveal that interleukin-22 can also promote ‘‘stemness’’ in
human colorectal cancer via transcription factor STAT3-mediated epigenetic regulation of stem cell genes.Chronic inflammation facilitates cancer
development, as illustrated by the in-
creased incidence of colitis-associated
colon cancers (CAC) in patients with in-
flammatory bowel diseases (IBD) or liver
cancer in patients with hepatitis. Many
other cancers, including sporadic colo-
rectal cancer (CRC), do not initially arise
in an inflammatory context but later on
induce ‘‘tumor-elicited inflammation.’’
This inflammatory reaction acquired by
tumors is important, because nonspecific
inhibition of inflammation with aspirin
reduces cancer-related deaths, and high
interleukin-17 (IL-17) expression marks
CRC with poor prognosis (Tosolini et al.,2011). Proinflammatory cytokines, whose
expression is elevated in tumors, mediate
crosstalk between immune and cancer
cells. Receptors for such cytokines are
often expressed by epithelial cells and
are able to activate key transcription
factors, such as NF-kB and signal trans-
ducer and activator of transcription 3
(STAT3), that normally maintain tissue
homeostasis, but when deregulated can
contribute to malignant transformation.
The ability of cytokines to activate key
oncogenic signaling hubs has focused
research toward understanding their role
in promoting cell proliferation and survival
during tumorigenesis. In this issue ofImmunity, Kryczek et al. (2014) demon-
strate that IL-22 promotes human CRC
relying on STAT3-dependent pathway of
epigenetic activation of genes respon-
sible for maintenance of CRC cancer
stem cells, thus adding a new dimension
to what we know about how cytokines
promote cancer through other, potentially
diverse, mechanisms.
IL-22 has recently emerged as a key
regulator of epithelial homeostasis at
multiple organ sites, including skin, liver,
lung, and gastrointestinal tract. IL-22 trig-
gers phosphorylation and activation of
STAT3 to mediate its protective effects
on the intestinal epithelium during colitis40, May 15, 2014 ª2014 Elsevier Inc. 639
